GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis
Authors' conclusion
In this propensity score-matched real-world cohort of adults with T1D, GLP-1-based therapy was associated with lower risks of all-cause mortality, HF, adapted-MACE, hospitalisation, and hypoglycemia without increased DKA risk.
Study context
- Population
- Adults with T1D, TriNetX global health research networkpropensity-matched cohort
- Participants
- 4,088 vs 4,088
- Exposure
- GLP-1-based therapy vs no GLP-1-based therapy
- GLP-1-based therapyn = 4,088
- No GLP-1-based therapyn = 4,088reference
- Outcome
- Major clinical outcomes
- Follow-up
- Event accrual from 6 months after therapy initiation
Methodological detailspropensity score matching (1:1), real-world, TriNetX global health research network
- Propensity score matching (1:1)
- Real-world
- TriNetX global health research network
Main finding
As reported in the abstract
Each group vs no GLP-1-based therapyEstimate (95% CI)
GLP-1-based therapy
HR (all-cause mortality) 0.67(0.46–0.98)
GLP-1-based therapy
HR (HF) 0.38(0.21–0.67)
GLP-1-based therapy
HR (adapted-MACE) 0.61(0.40–0.94)
GLP-1-based therapy
HR (all-cause hospitalisation) 0.70(0.51–0.96)
Observational data: associations, not effects.
Safety
| Outcome | HR (95% CI) | |
|---|---|---|
| Hypoglycemia | 0.72 (0.55–0.95) | |
| 0.512Hazard ratio (log scale) |
Diabetic ketoacidosis (DKA)
- DKA incidence was not increased
Pancreatitis
- Pancreatitis events in both groups
- Less than 10 (0.2%)
Original publication
GLP ‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis. Diabetes Obes Metab. Published 6 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →